河北医学
河北醫學
하북의학
HEBEI MEDICINE
2015年
10期
1645-1648
,共4页
老年%冠状动脉疾病%内皮血管%降血脂药
老年%冠狀動脈疾病%內皮血管%降血脂藥
노년%관상동맥질병%내피혈관%강혈지약
Elder%Coronary disease%Endothelium vascular%Antilipemic agents
目的：观察瑞舒伐他汀联合普罗布考对老老年不稳定心绞痛（ UA）患者的有效性及安全性。方法：78例80岁以上UA患者随机分到他汀组瑞舒伐他汀5～10mg／d，n＝39）与联合治疗组（瑞舒伐他汀5～10mg／d和普罗布考500mg／d，n＝39）。治疗前、1周、4周、2个月及半年后分别测血清血脂、血糖、肝肾功能及肌酸激酶，并应用高频超声测肱动脉血流介导的内皮依赖血管舒张功能（ FMD ）和由硝酸甘油诱导的内皮非依赖血管舒张功能（ NMD）。结果：两组血清总胆固醇、低密度脂蛋白胆固醇（ LDL－C）明显低于治疗前，联合治疗组血清总胆固醇及低密度脂蛋白胆固醇水平下降较他汀组更明显（P＜O．05）。治疗1周后，两组FMD及NMD均明显高于治疗前（P＜0．01），两组比较差异无统计学意义。随着治疗时间的延长，内皮功能持续改善，半年后联合治疗组FMD明显高于他汀组（7．01％±0．736％％vs 5．10％±0．91％P＜0．0．05）；两组肝肾功能及肌酸激酶均无明显异常，空腹血糖无改变。结论：瑞舒伐他汀联合普罗布考对老老年不稳定心绞痛患者安全有效，联合治疗较单用瑞舒伐他汀能更明显地改善血管内皮功能。
目的：觀察瑞舒伐他汀聯閤普囉佈攷對老老年不穩定心絞痛（ UA）患者的有效性及安全性。方法：78例80歲以上UA患者隨機分到他汀組瑞舒伐他汀5～10mg／d，n＝39）與聯閤治療組（瑞舒伐他汀5～10mg／d和普囉佈攷500mg／d，n＝39）。治療前、1週、4週、2箇月及半年後分彆測血清血脂、血糖、肝腎功能及肌痠激酶，併應用高頻超聲測肱動脈血流介導的內皮依賴血管舒張功能（ FMD ）和由硝痠甘油誘導的內皮非依賴血管舒張功能（ NMD）。結果：兩組血清總膽固醇、低密度脂蛋白膽固醇（ LDL－C）明顯低于治療前，聯閤治療組血清總膽固醇及低密度脂蛋白膽固醇水平下降較他汀組更明顯（P＜O．05）。治療1週後，兩組FMD及NMD均明顯高于治療前（P＜0．01），兩組比較差異無統計學意義。隨著治療時間的延長，內皮功能持續改善，半年後聯閤治療組FMD明顯高于他汀組（7．01％±0．736％％vs 5．10％±0．91％P＜0．0．05）；兩組肝腎功能及肌痠激酶均無明顯異常，空腹血糖無改變。結論：瑞舒伐他汀聯閤普囉佈攷對老老年不穩定心絞痛患者安全有效，聯閤治療較單用瑞舒伐他汀能更明顯地改善血管內皮功能。
목적：관찰서서벌타정연합보라포고대로노년불은정심교통（ UA）환자적유효성급안전성。방법：78례80세이상UA환자수궤분도타정조서서벌타정5～10mg／d，n＝39）여연합치료조（서서벌타정5～10mg／d화보라포고500mg／d，n＝39）。치료전、1주、4주、2개월급반년후분별측혈청혈지、혈당、간신공능급기산격매，병응용고빈초성측굉동맥혈류개도적내피의뢰혈관서장공능（ FMD ）화유초산감유유도적내피비의뢰혈관서장공능（ NMD）。결과：량조혈청총담고순、저밀도지단백담고순（ LDL－C）명현저우치료전，연합치료조혈청총담고순급저밀도지단백담고순수평하강교타정조경명현（P＜O．05）。치료1주후，량조FMD급NMD균명현고우치료전（P＜0．01），량조비교차이무통계학의의。수착치료시간적연장，내피공능지속개선，반년후연합치료조FMD명현고우타정조（7．01％±0．736％％vs 5．10％±0．91％P＜0．0．05）；량조간신공능급기산격매균무명현이상，공복혈당무개변。결론：서서벌타정연합보라포고대로노년불은정심교통환자안전유효，연합치료교단용서서벌타정능경명현지개선혈관내피공능。
Objective:To evaluate the study on effect and safety of rosuvastatin combined with probucol in treatment of elder patients with acute coronary syndrome ( ACS) .Methods:78 patients, aged >80 years, with ACS were randomized to receive rosuvastatin (10 mg/d)and probucol(500 mg/d,combination group,n=39)or rosuvastatin (10 mg/d)alone(rosuvastatin group).Endothelium dependent flow mediated dilatation (FMD)and endothelium-independent sublingual nitroglycerin-mediated dilatation(NMD)as well as the lev-els of lipids,glucose,liver and renal funtion,and creatine kinase(CK) were assessed at baseline,1 week ,4 weeks,2 mouths and a half of year after therapy .Result: Compared to baseline ,the levels of total cholester and LDL-C were significantly reduced in both groups .FMD equally increased after l week in both groups ( ro-suvastatin group:3.79%±0.79%vs.1.10%±0.44%,combination group:3.80%±0.38%vs.1.04%±0.37%;P<0.01).Post a half of year therapy ,FMD increase was significantly higher in combination group than that in rosuvastatin group(7.01%±0.73 6%%vs.5.10%±0.91%P<0.0.05).Liver and renal function, glucose,and CK had no significant change .Conclusion:The combined rosuvastatin and probucol in treatment of elder pa-tient with ACS is significantly effective and comparatively safe; The combined rosuvastatin and probucol is superior to rosuvastatin alone on improving endothelial function .
